Relationship between clone metrics and clinical outcome in clonal cytopenia.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
16 09 2021
Historique:
received: 15 02 2021
accepted: 21 06 2021
pubmed: 14 7 2021
medline: 15 12 2021
entrez: 13 7 2021
Statut: ppublish

Résumé

Clonal cytopenia of undetermined significance (CCUS) is associated with an increased risk of developing a myeloid neoplasm with myelodysplasia (MN). To identify the features of the mutant clone(s) that is associated with clinical phenotype and progression, we studied the following cohorts of individuals: 311 patients with idiopathic cytopenia of undetermined significance (ICUS), 532 community-dwelling individuals without hematologic phenotype (n = 355) or with unexplained anemia (n = 177), and 592 patients with overt MN. Ninety-two of 311 (30%) patients with ICUS carried a somatic genetic lesion that signaled CCUS. Clonal hematopoiesis (CH) was detected in 19.7% and 27.7% of nonanemic and anemic community-dwelling individuals, respectively. Different mutation patterns and variant allele frequencies (VAFs) (clone metrics parameters) were observed in the conditions studied. Recurrent mutation patterns exhibited different VAFs associated with marrow dysplasia (0.17-0.48), indicating variable clinical expressivity of mutant clones. Unsupervised clustering analysis based on mutation profiles identified 2 major clusters, characterized by isolated DNMT3A mutations (CH-like cluster) or combinatorial mutation patterns (MN-like cluster), and showing different overall survival (HR, 1.8). In patients with CCUS, the 2 clusters had different risk of progression to MN (HR, 2.7). Within the MN-like cluster, distinct subsets with different risk of progression to MN were identified based on clone metrics. These findings unveil marked variability in the clinical expressivity of myeloid driver genes and underline the limitations of morphologic dysplasia for clinical staging of mutant hematopoietic clones. Clone metrics appears to be critical for informing clinical decision-making in patients with clonal cytopenia.

Identifiants

pubmed: 34255818
pii: S0006-4971(21)01347-1
doi: 10.1182/blood.2021011323
doi:

Substances chimiques

DNMT3A protein, human 0
DNA Methyltransferase 3A EC 2.1.1.37

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

965-976

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Informations de copyright

© 2021 by The American Society of Hematology.

Auteurs

Anna Gallì (A)

Department of Hematology Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione Policlinico San Matteo, Pavia, Italy.

Gabriele Todisco (G)

Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden.

Eulalia Catamo (E)

Department of Medicine, Surgery, and Health Sciences, University of Trieste, Trieste, Italy.
Institute for Maternal and Child Health-IRCCS Burlo Garofolo, Trieste, Italy.

Cinzia Sala (C)

Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy.

Chiara Elena (C)

Department of Hematology Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione Policlinico San Matteo, Pavia, Italy.

Sara Pozzi (S)

Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Elisa Bono (E)

Department of Hematology Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione Policlinico San Matteo, Pavia, Italy.
Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Virginia Valeria Ferretti (VV)

Unit of Clinical Epidemiology and Biometrics, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.

Ettore Rizzo (E)

enGenome srl, Pavia, Italy; and.

Elisabetta Molteni (E)

Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Silvia Zibellini (S)

Department of Hematology Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione Policlinico San Matteo, Pavia, Italy.

Martina Sarchi (M)

Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Emanuela Boveri (E)

Department of Pathology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.

Jacqueline Ferrari (J)

Department of Hematology Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione Policlinico San Matteo, Pavia, Italy.
Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Nicolas Fiorelli (N)

Department of Hematology Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione Policlinico San Matteo, Pavia, Italy.
Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Clara Camaschella (C)

Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy.

Paolo Gasparini (P)

Department of Medicine, Surgery, and Health Sciences, University of Trieste, Trieste, Italy.
Institute for Maternal and Child Health-IRCCS Burlo Garofolo, Trieste, Italy.

Daniela Toniolo (D)

Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy.

Mario Cazzola (M)

Department of Hematology Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione Policlinico San Matteo, Pavia, Italy.
Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Luca Malcovati (L)

Department of Hematology Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione Policlinico San Matteo, Pavia, Italy.
Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH